EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Kala Bio's Enterprise Value is $6.42 Mil.
Kala Bio's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was $-29.60 Mil. Therefore, Kala Bio's EV-to-FCF for today is -0.22.
The historical rank and industry rank for Kala Bio's EV-to-FCF or its related term are showing as below:
LTS:0JQ2'
s EV-to-FCF Range Over the Past 10 Years
Min: -6.56 Med: -1.19 Max: 0.27
Current: -0.22
During the past 9 years, the highest EV-to-FCF of Kala Bio was 0.27. The lowest was -6.56. And the median was -1.19.
LTS:0JQ2's EV-to-FCF is ranked worse than 100% of 372
companies
in the Biotechnology industry
Industry Median: 8.36
vs LTS:0JQ2: -0.22
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-05-25), Kala Bio's stock price is $6.6266.
Kala Bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-15.150. Therefore, Kala Bio's PE Ratio for today is At Loss.
Kala Bio EV-to-FCF Historical Data
The historical data trend for Kala Bio's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Kala Bio's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kala Bio's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kala Bio's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Kala Bio's EV-to-FCF falls into.
Kala Bio's current Enterprise Value is $6.42 Mil.
Kala Bio's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-29.60 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kala Bio (LTS:0JQ2) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Kala Bio's share price for today is $6.6266.
Kala Bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-15.150.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Kala Bio EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Kala Bio's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing innovative therapies for rare and severe eye diseases. KALA's lead product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LTS:0JQ2 has been successfully added to your 